Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | NPC1 | O15118 | 4/20 | 0.75 |
| ▸ | RAB9A | P51151 | 4/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.75 |
| ▸ | PLK1 | P53350 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | ALPL | P05186 | 3/20 | 0.62 |
| ▸ | HPGDS | O60760 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23755314 | 0.86 | MAPT (0.70) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL2888912 | 0.86 | MAPT (1.00) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL16730821 | 0.85 | MAPT (0.69) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL13710322 | 0.85 | MAPT (0.69) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL595997 | 0.84 | ALPL (0.75) | MAPTNPC1RAB9AL3MBTL1TP53 | |
| SCHEMBL30716607 | 0.84 | ALPL (0.74) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL16699171 | 0.84 | ALPL (0.74) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL16700939 | 0.84 | MAPT (0.67) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL3448593 | 0.83 | MAPT (0.78) | MAPTSMN1; SMN2PLK1TP53ALPL | |
| SCHEMBL11982068 | 0.82 | MAPT (0.76) | MAPTSMN1; SMN2NPC1RAB9APLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| EP-1572682-A4 | ACYCLIC PYRAZOLE COMPOUNDS | PHARMACIA CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1572682-A2 | ACYCLIC PYRAZOLE COMPOUNDS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040152739-A1 | Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-08-05 | — | — | US | disclosed |
| WO-2004058176-A2 | ACYCLIC PYRAZOLE COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MKNK2, MAPKAPK2, MAP3K2 | MAPT 1363/4885SMN1; SMN2 3576/4885NPC1 3564/4885 |
| US-20040152739-A1 | Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MAPKAPK2, MAP3K2, MAP4K2 | MAPT 2038/4885SMN1; SMN2 2997/4885NPC1 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.